Skip to main content
. 2023 Nov 20;24(1):29–39. doi: 10.1007/s40268-023-00445-3

Table 3.

Results of adverse events in the methylphenidate and atomoxetine groups

Methylphenidate [n (%)] Atomoxetine [n (%)]
Total number of subjects with AEs 255 (47.8) 277 (56.8)
 Decreased appetite 174 (32.6) 177 (36.3)
 Abdominal pain 12 (2.3) 18 (3.7)
 Vomiting 8 (1.5) 10 (2.0)
 Nausea 8 (1.5) 12 (2.5)
 Constipation 2 (0.4) 9 (1.8)
 Weight loss 20 (3.8) 19 (3.9)
 Sleep disturbances (insomnia/fractured sleep) 64 (12.0) 24 (4.9)
 Somnolence 0 61 (12.5)
 Tics 20 (3.8) 7 (1.4)
 Headache 9 (1.7) 10 (2.0)
 Dizziness 6 (1.1) 10 (2.0)
 Fatigue 0 3 (0.6)
 Psychiatric problems (irritability, aggression, emotional instability, depression, crying, anxiety, sadness, etc.) 24 (4.5) 71 (14.5)
 Chest tightness/palpitation 7 (1.3) 3 (0.6)
 Abnormal ECG 15 (2.8) 10 (2.0)
 Transient transaminase elevation 7 (1.3) 3 (0.6)
 Dry mouth 3 (0.6) 3 (0.6)
 Hair pulling 2 (0.4) 0
 Eyelash pulling 1 (0.2) 0
 Eyebrow alopecia 0 1 (0.2)
 Frequent micturition 1 (0.2) 1 (0.2)
 Oral ulcer 1 (0.2) 0
 Rash 1 (0.2) 7 (1.4)
 Lip cracking 1 (0.2) 1 (0.2)
 Skin itch 0 2 (0.4)
 Fever 1 (0.2) 1 (0.2)
 Enuresis 0 2 (0.4)
 Urinary hesitancy 0 1 (0.2)
 Tinnitus 0 1 (0.2)
 Earache 0 1 (0.2)
 Hand trembling 0 1 (0.2)

AEs adverse events, ECG electrocardiogram